Medical device company ResMed (NYSE:RMD) announced in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.

William Blair lowered their Q3 2025 EPS estimates for ResMed in a research report issued on Monday, February 3rd. William Blair analyst M. Andrew now anticipates that the medical equipment provider ...

Reports Q2 revenue $1.28B, consensus $1.27B. “Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS ...

We are very excited to have Sleep Health become mainstream. Interestingly, ResMed products were on display in the massive Samsung booth. Samsung was touting their new Galaxy Watch's sleep apnea ...

ResMed has beaten its earnings forecast in the second quarter despite concerns from investors around weight loss drugs ...

ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

The great quarter was driven by high demand for sleep-related products and growth in digital health solutions. As a specialist in sleep and respiratory health, ResMed built its reputation through ...

We are very excited to have sleep health become mainstream. Interestingly, ResMed's products were on display in the massive Samsung booth. Samsung was touting their new Galaxy watches' sleep apnea ...